» Articles » PMID: 25894392

Increase in Nonhepatic Diagnoses Among Persons with Hepatitis C Hospitalized for Any Cause, United States, 2004-2011

Overview
Journal J Viral Hepat
Specialty Gastroenterology
Date 2015 Apr 21
PMID 25894392
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Although persons with hepatitis C virus (HCV) infection may experience nonhepatic illnesses, little is known about the frequency of and trends in such conditions in a population-based sample of HCV-infected persons. Using hospitalization data collected during 2004-2011 from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project, we examined trends in comorbidities among all hospitalizations that included either a principal or secondary HCV diagnostic code (i.e., HCV was not necessarily the cause for hospitalization). We also compared comorbidities among all persons aged 45-64 years hospitalized with and without principal or secondary HCV diagnostic codes. The estimated number of hospitalizations among persons with HCV infection increased from 850,490 in 2004-2005 to 1,178,633 in 2010-2011; mean age at hospitalization was 50 years in 2004-2005 and 52.5 years in 2010-2011. There were significant increases in the prevalence of most medical and psychiatric comorbidities; the largest were for lipid disorders, chronic kidney disease and obesity. Among HCV-infected aged 45-64 persons hospitalized for any cause, the prevalence of alcohol /substance abuse, mental disorders, chronic kidney disease, pneumonia, hepatitis B virus infection and HIV infection were significantly higher than those aged 45-64 persons hospitalized without HCV infection (P < 0.001 for all). The prevalence of cryoglobulinaemia, vasculitis, nephrotic syndrome or membranoproliferative glomerulonephritis and porphyria cutanea tarda among hospitalizations with HCV infection was consistently low during the study period (i.e., <0.5%). The increase we observed in nonhepatic comorbidities associated with a high risk of HCV-related complications has important implications for the current HCV treatment recommendations in a greatly expanded treatment population.

Citing Articles

Renal Manifestations of Chronic Hepatitis C: A Review.

Sohal A, Singh C, Bhalla A, Kalsi H, Roytman M J Clin Med. 2024; 13(18).

PMID: 39337023 PMC: 11433393. DOI: 10.3390/jcm13185536.


Temporal Trends in Hepatitis C-Related Hospitalizations, United States, 2000-2019.

Hofmeister M, Zhong Y, Moorman A, Samuel C, Teshale E, Spradling P Clin Infect Dis. 2023; 77(12):1668-1675.

PMID: 37463305 PMC: 11017377. DOI: 10.1093/cid/ciad425.


Renal function trajectories in hepatitis C infection: differences between renal healthy and chronic kidney disease individuals.

Hsu C, Lai T, Chen Y, Tseng Y, Lee C, Chen C Sci Rep. 2021; 11(1):17197.

PMID: 34433887 PMC: 8387367. DOI: 10.1038/s41598-021-96782-x.


Association of Infection With Human Papillomavirus and Development of End-Stage Kidney Disease in Taiwan.

Chang R, Chen M, Lin C, Hung Y, Cheng-Chung Wei J JAMA Netw Open. 2020; 3(10):e2022107.

PMID: 33090225 PMC: 7582124. DOI: 10.1001/jamanetworkopen.2020.22107.


Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational....

Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D J Viral Hepat. 2019; 26(6):685-696.

PMID: 30739368 PMC: 6849558. DOI: 10.1111/jvh.13080.


References
1.
Xu F, Tong X, Leidner A . Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase. Health Aff (Millwood). 2014; 33(10):1728-35. DOI: 10.1377/hlthaff.2014.0096. View

2.
Johnson R, Gretch D, Couser W, Alpers C, Wilson J, Chung M . Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int. 1994; 46(6):1700-4. DOI: 10.1038/ki.1994.471. View

3.
Kowdley K, Gordon S, Reddy K, Rossaro L, Bernstein D, Lawitz E . Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370(20):1879-88. DOI: 10.1056/NEJMoa1402355. View

4.
Galbraith J, Donnelly J, Franco R, Overton E, Rodgers J, Wang H . National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. Clin Infect Dis. 2014; 59(6):755-64. PMC: 4200046. DOI: 10.1093/cid/ciu427. View

5.
Gumber S, Chopra S . Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med. 1995; 123(8):615-20. DOI: 10.7326/0003-4819-123-8-199510150-00008. View